Lazabemide
Chemical compound
- none
- Development terminated
- N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
- 103878-84-8
- 71307
- 6640
- 64426
- 420HD787N9
- D04681
- DTXSID2048294
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References
- ^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.
{{cite book}}:|journal=ignored (help)
- v
- t
- e
Antiparkinson agents (N04)
| DA precursors | |
|---|---|
| DA receptor agonists |
|
| MAO-B inhibitors | |
| COMT inhibitors | |
| AAAD inhibitors |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
